-
Article
Open AccessTreatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stop** therapy) following frontline nilotinib tre...
-
Article
Open AccessLong-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Tyrosine kinase inhibitors represent today’s treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective ra...
-
Article
Open AccessFrontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
The Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study included 1089 patients with newly diagnosed chronic myeloid leukemia in chronic phase. The rate of deep ...
-
Article
Open AccessLeukemia and risk of recurrent Escherichia coli bacteremia: genoty** implicates E. coli translocation from the colon to the bloodstream
In patients with leukemia, the portal(s) and reasons for the persistence of an Escherichia coli recurrent bacteremia remain unclear. Adult Hematology Clinic (AHC) databases at the State Clinical Hospital in Gdańs...
-
Article
Open AccessAn evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM) patients who have a long-term response to thalidomide...
